Melitracen

Melitracen
Systematic (IUPAC) name
3-(10,10-dimethylanthracen-9(10H)-ylidene)-N,N-dimethylpropan-1-amine
Clinical data
AHFS/Drugs.com International Drug Names
  • ℞ (Prescription only)
Oral, IM
Identifiers
5118-29-6 
N06AA14
PubChem CID 25382
ChemSpider 23697 Yes
UNII Q7T0Y1109Z Yes
KEGG D08171 Yes
ChEMBL CHEMBL110094 Yes
Chemical data
Formula C21H25N
291.43 g/mol
  (what is this?)  (verify)

Melitracen (Adaptol, Dixeran, Melixeran, Thymeol, Trausabun) is a tricyclic antidepressant (TCA) marketed in Europe and Japan by Lundbeck and Takeda, respectively, for the treatment of depression and anxiety.[1][2][3][4] In addition to single drug preparations, it is also available as Deanxit, a combination product containing both melitracen and flupentixol.[5][6][7][8]

The pharmacology of melitracen has not been properly investigated and is largely unknown, but it is likely to act in a similar manner to other TCAs. Indeed, melitracen is reported to have imipramine and amitriptyline-like effects and efficacy against depression and anxiety, though with improved tolerability and a somewhat faster onset of action.[9][10]

See also

References

  1. ↑ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. ISBN 3-88763-075-0.
  2. ↑ Hall, Chapman and; Chemical Abstracts Service, American Chemical Society; Rhodes, P. H (1996). Dictionary of organic compounds. London: Chapman & Hall. ISBN 0-412-54090-8.
  3. ↑ O'Neil, Maryadele J. (2001). The Merck index: an encyclopedia of chemicals, drugs, and biologicals. Rahway, NJ: Merck Research Laboratories. ISBN 0-911910-13-1.
  4. ↑ José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens (2007). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. ISBN 3-527-31058-4.
  5. ↑ Muller, Niels F; Dessing, Rudolf P; Pharmacy, European Society of Clinical (1998). European Drug Index, 4th Edition. Boca Raton: CRC Press. ISBN 3-7692-2114-1.
  6. ↑ Van Moffaert M, Dierick M, De Meulemeester F, Vereecken A (1983). "Treatment of depressive anxiety states associated with psychosomatic symptoms. A double-blind multicentre clinical study: mianserin versus melitracen-flupentixol". Acta Psychiatrica Belgica 83 (5): 525–39. PMID 6670581.
  7. ↑ Bin Yaacob H (April 1985). "Flupenthixol and Melitracen in the management of trigeminal neuralgia". Dental Journal of Malaysia 8 (2): 37–8. PMID 3917005.
  8. ↑ Hashash JG; Abdul-Baki H; Azar C et al. (June 2008). "Clinical trial: a randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia". Alimentary Pharmacology & Therapeutics 27 (11): 1148–55. doi:10.1111/j.1365-2036.2008.03677.x. PMID 18331614.
  9. ↑ Aronson, Jeffrey Kenneth (2008). Meyler's Side Effects of Psychiatric Drugs (Meylers Side Effects). Amsterdam: Elsevier Science. ISBN 0-444-53266-8.
  10. ↑ Author Unknown (1970). Ann Reports Medicinal Chem V5 (v. 5). Boston: Academic Press. ISBN 0-12-040505-9.